NDAINTRAVENOUSPOWDER
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
TIGECYCLINE (tigecycline) by Fresenius Kabi. Approved for bacterial pneumonia, complicated intra-abdominal infections, complicated skin and skin structure infections and 3 more indications. First approved in 2016.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tigecycline is a broad-spectrum intravenous tetracycline-class antibiotic used to treat complicated bacterial infections including pneumonia, intra-abdominal infections, and skin/soft tissue infections. It represents an advanced tetracycline derivative with expanded gram-negative and anaerobic coverage compared to earlier-generation tetracyclines.
Peak
Tigecycline is at peak lifecycle with moderate competitive spending ($597K for Fresenius Kabi formulation), suggesting stable but not rapidly growing commercial opportunity.
Mechanism of Action
Pharmacologic Class:
Tetracycline-class Antibacterial
Worked on TIGECYCLINE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.